CG ONCOLOGY INC.

CGON11 Dec 2024
Healthcare
$32.08
-0.11 (-10.62%)
Lowest Today
$30.3
Highest Today
$32.27
Today’s Open
$32.08
Prev. Close
$33.7
52 Week High
$50.23
52 Week Low
$25.77
To Invest in CG ONCOLOGY INC.

CG ONCOLOGY INC.

Healthcare
CGON11 Dec 2024
-0.11 (-10.62%)
1M
3M
6M
1Y
5Y
Low
$30.3
Day’s Range
High
$32.26
30.3
52 Week Low
$25.77
52-Week Range
52 Week High
$50.23
25.77
1 Day
-
1 Week
-5.87%
1 month return
-15.18%
3 month return
-7.27%
6 month return
-3.7%
1 Year return
-
3 Years return
-
5 Years return
-
10 Years return
-

Market Status

Fundamentals
Market Cap
2247.33 mln
PB Ratio
4.36
PE Ratio
0
Enterprise Value
1798.9 mln
Total Assets
199.3 mln
Volume

Company Financials

Fund house & investment objective

Company Information
CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.
Organisation
CG ONCOLOGY INC.
Employees
61
Industry
Biotechnology
CEO
Mr. Arthur  Kuan
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step

Click here to see your activities